FSH: the pituitary's signal to the gonads
Follicle Stimulating Hormone (FSH) is a signaling hormone in your bloodstream, made by the front part of the pituitary gland at the base of the brain (anterior pituitary gonadotropin). Specialized pituitary cells release FSH under cues from the brain (gonadotropin-releasing hormone, GnRH). An FSH blood test simply measures how much of this hormone is circulating at a given moment, capturing one piece of the body's reproductive control system (the hypothalamic–pituitary–gonadal axis).
What it does: In ovaries, FSH drives the growth of fluid-filled follicles and the hormone-making cells that support them (granulosa cells), leading to estrogen (estradiol) production and priming for ovulation. In testes, FSH activates support cells (Sertoli cells) that nurture sperm formation (spermatogenesis) and make inhibin B. Because FSH output changes with feedback from the ovaries or testes (sex steroids and inhibin), its level reflects how the pituitary and gonads are communicating, and the capacity of these tissues to develop eggs or produce sperm.
Why FSH opens a window on the reproductive axis
FSH is a pituitary "signal" that tells ovaries to mature follicles and make estradiol, and tells testes to support sperm production. Because sex hormones guide bones, brain, metabolism, and cardiovascular tone, FSH is a window into the entire hypothalamic–pituitary–gonadal axis, fertility potential, and overall hormonal balance.
Reading FSH across cycle, sex, and life stage
In menstruating adults, FSH naturally fluctuates: low-to-mid single digits through most of the cycle with a modest bump around ovulation. Men usually sit in a steady low-to-mid single-digit range. After menopause it rises substantially, often several-fold above premenopausal values. Children are very low before puberty, then rise into adolescent ranges. In general, "healthy" values live in the context-appropriate middle rather than at extremes.
Low values usually reflect reduced pituitary drive or hypothalamic suppression (secondary hypogonadism). In women, this can mean irregular or absent cycles and anovulation with lower estrogen; in men, reduced spermatogenesis with lower intratesticular testosterone. Common contexts include pituitary disorders, high prolactin, severe stress or illness, under‑nutrition, and exposure to external sex steroids. Pregnancy, lactation, and many hormonal contraceptives physiologically suppress FSH. Low-for-age values are normal before puberty. When values are lower than expected for age and sex, that can occur with functional hypothalamic states (stress, undernutrition, intense training), pituitary disorders, high prolactin, or thyroid-related signals. Consequences are low estradiol or testosterone: irregular or absent periods, infertility, low libido, erectile issues, low bone density, fatigue, and delayed puberty in youth.
High values usually reflect reduced ovarian or testicular feedback (primary gonadal dysfunction). In women, this is typical after menopause and in premature ovarian insufficiency, with systemic effects of low estrogen on bones, vasomotor tone, and lipids. In men, high FSH suggests impaired seminiferous tubules (e.g., prior chemotherapy, mumps orchitis, or chromosomal causes) with low fertility and androgen deficiency features. In children, high-for-age values warrant age‑specific interpretation. When values are higher than expected, the pituitary is "shouting" because the ovaries or testes aren't responding (primary gonadal failure). This is typical in natural menopause and can appear with primary ovarian insufficiency, gonadotoxic chemotherapy/radiation, Turner or Klinefelter syndromes, or testicular injury. Effects include infertility, hot flashes, night sweats, vaginal dryness, mood and sleep changes, and in men low libido and reduced muscle mass.
What can shift an FSH reading
Interpretation depends on age, sex, menstrual cycle day, and assay. FSH is pulsatile and is best interpreted with LH, estradiol or testosterone, and sometimes AMH or inhibin B. Medications, pregnancy, lactation, acute illness, and lab-specific ranges materially affect results.
Pairing FSH with LH, estradiol, AMH, and testosterone
Big picture: FSH integrates with LH, estradiol/testosterone, prolactin, and thyroid status. Tracking it helps explain menstrual patterns, puberty timing, fertility, and the menopausal transition—and signals downstream risks in bone, cardiometabolic health, and quality of life when sex-steroid levels are chronically low. FSH reflects the health of the hypothalamic–pituitary–gonadal axis and the feedback from sex steroids (estradiol, progesterone, testosterone) and inhibins. Because these hormones influence fertility, bone remodeling, body composition, mood, and cognition, FSH is a window into broader metabolic and reproductive stability. Being in range suggests coordinated signaling between brain and gonads with appropriate sex steroid feedback. In cycling women, it supports follicle development and predictable ovulation; in men, steady support of sperm production. For reproductive‑age adults, basal FSH typically sits in the low-to-mid portion of phase‑specific reference ranges outside the ovulatory surge, indicating hormonal stability and balanced bone and metabolic effects.
FAQs
FSH testing measures the concentration of FSH in your blood to assess pituitary-gonadal signaling, ovarian reserve in females, and spermatogenic support in males.
Testing FSH helps with fertility planning, understanding irregular or absent periods, mapping perimenopause or menopause, evaluating sperm production capacity, and assessing the effects of training, nutrition, stress, illness, and medications on the reproductive axis.
Frequency depends on your goals. For cycle assessment, test in the early follicular phase (days 2–4). Males can test any day. Repeat when symptoms, medications, or training loads change.
Age, menstrual-cycle phase, hypothalamic or pituitary signaling, prolactin, stress, illness, under-fueling, overtraining, and exogenous hormones (including contraception, anabolic steroids, or gender-affirming therapy) can all influence FSH.
No special preparation is typically required. For menstrual-cycle assessment, collect on days 2–4; males can collect any day. Note any medications or hormones in use when interpreting results.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Marques, P., De Sousa Lages, A., Skorupskaite, K., Rozario, K. S., Anderson, R. A., & George, J. T. (2024). Physiology of GnRH and gonadotrophin secretion. In Endotext. MDText.com. https://www.ncbi.nlm.nih.gov/books/NBK279070/
- Harlow, S. D., Gass, M., Hall, J. E., Lobo, R., Maki, P., Rebar, R. W., Sherman, S., Sluss, P. M., & de Villiers, T. J. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Menopause, 19(4), 387-395. https://doi.org/10.1097/gme.0b013e31824d8f40
- Moolhuijsen, L. M. E., & Visser, J. A. (2020). Anti-Müllerian hormone and ovarian reserve: Update on assessing ovarian function. The Journal of Clinical Endocrinology & Metabolism, 105(11), 3361-3373. https://doi.org/10.1210/clinem/dgaa513
- Casteel, C. O., & Singh, G. (2023). Physiology, gonadotropin-releasing hormone. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558992/
- Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007). Position statement: Utility, limitations, and pitfalls in measuring testosterone: An Endocrine Society position statement. The Journal of Clinical Endocrinology & Metabolism, 92(2), 405-413. https://doi.org/10.1210/jc.2006-1864






































.avif)
